STOCK TITAN

IBRX (NASDAQ: IBRX) holder plans Rule 144 sale of 50,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

A holder of ImmunityBio (symbol IBRX) has filed a Rule 144 notice to sell 50,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $197,500 based on the figures in the notice. The filing lists 984,965,179 shares outstanding as a baseline figure for the issuer’s common stock.

The securities to be sold were acquired on 01/16/2026 by an exercise of stock options from the issuer, paid in cash, with the same date shown for payment. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, consistent with the representations referenced in Rule 144 and any Rule 10b5-1 trading plan disclosures.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the IBRX Form 144 filing disclose?

The Form 144 filing for IBRX discloses a planned sale of 50,000 shares of common stock by a holder relying on Rule 144.

How many IBRX shares are planned to be sold under this Form 144?

The notice covers a proposed sale of 50,000 shares of IBRX common stock.

What is the aggregate market value of the IBRX shares in this Form 144?

The filing lists an aggregate market value of $197,500 for the 50,000 common shares to be sold.

How and when were the IBRX shares in this Form 144 acquired?

The 50,000 IBRX common shares were acquired on 01/16/2026 through an exercise of stock options from the issuer, with payment in cash on the same date.

Which broker and exchange are involved in this IBRX Form 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.

How many IBRX shares are shown as outstanding in the Form 144?

The Form 144 notes that there are 984,965,179 shares of IBRX common stock outstanding as a baseline figure.

What representation does the seller make in the IBRX Form 144?

By signing, the seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Immunitybio Inc

NASDAQ:IBRX

IBRX Rankings

IBRX Latest News

IBRX Latest SEC Filings

IBRX Stock Data

3.89B
330.77M
69.2%
13.26%
7.97%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO